title: Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
abstract: This study examines the contribution of the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein genes of bovine parainfluenza virus type 3 (BPIV3) to its restricted replication in the respiratory tract of nonhuman primates. A chimeric recombinant human parainfluenza type 3 virus (HPIV3) containing BPIV3 F and HN glycoprotein genes in place of its own and the reciprocal recombinant consisting of BPIV3 bearing the HPIV3 F and HN genes (rBPIV3-F(H)HN(H)) were generated to assess the effect of glycoprotein substitution on replication of HPIV3 and BPIV3 in the upper and lower respiratory tract of rhesus monkeys. The chimeric viruses were readily recovered and replicated in simian LLC-MK2 cells to a level comparable to that of their parental viruses, suggesting that the heterologous glycoproteins were compatible with the PIV3 internal proteins. HPIV3 bearing the BPIV3 F and HN genes was restricted in replication in rhesus monkeys to a level similar to that of its BPIV3 parent virus, indicating that the glycoprotein genes of BPIV3 are major determinants of its host range restriction of replication in rhesus monkeys. rBPIV3-F(H)HN(H) replicated in rhesus monkeys to a level intermediate between that of HPIV3 and BPIV3. This observation indicates that the F and HN genes make a significant contribution to the overall attenuation of BPIV3 for rhesus monkeys. Furthermore, it shows that BPIV3 sequences outside the F and HN region also contribute to the attenuation phenotype in primates, a finding consistent with the previous demonstration that the nucleoprotein coding sequence of BPIV3 is a determinant of its attenuation for primates. Despite its restricted replication in the respiratory tract of rhesus monkeys, rBPIV3-F(H)HN(H) conferred a level of protection against challenge with HPIV3 that was indistinguishable from that induced by previous infection with wild-type HPIV3. The usefulness of rBPIV3-F(H)HN(H) as a vaccine candidate against HPIV3 and as a vector for other viral antigens is discussed.
authors.affiliation: Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. aschmidt@niaid.nih.gov
authors.forename: A C
authors.initials: AC
authors.lastname: Schmidt
authors.forename: J M
authors.initials: JM
authors.lastname: McAuliffe
authors.forename: A
authors.initials: A
authors.lastname: Huang
authors.forename: S R
authors.initials: SR
authors.lastname: Surman
authors.forename: J E
authors.initials: JE
authors.lastname: Bailly
authors.forename: W R
authors.initials: WR
authors.lastname: Elkins
authors.forename: P L
authors.initials: PL
authors.lastname: Collins
authors.forename: B R
authors.initials: BR
authors.lastname: Murphy
authors.forename: M H
authors.initials: MH
authors.lastname: Skiadopoulos
mesh_terms: D000818:Animals; D002417:Cattle; D002460:Cell Line; D015707:HN Protein / Q000502:physiology*; D006801:Humans; D011323:Primates; D018108:Respirovirus / Q000502:physiology*; D014760:Viral Fusion Proteins / Q000502:physiology*; D014779:Virus Replication
chemical_list: D015707:HN Protein; D014760:Viral Fusion Proteins